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Background: Colorectal cancer (CRC) is a disease of the elderly. However, geriatric patients are often excluded from
clinical trials. The combination of capecitabine, oxaliplatin and bevacizumab (XELOX/BEV) has not been assessed in
an elderly population.
Methods: We conducted a phase II study of XELOX plus bevacizumab combination as first line treatment in elderly
patients with metastatic CRC. Treatment consisted of capecitabine 750 mg/m2 twice a day during days 1–7,
oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1. Treatment was repeated every 14 days. The primary
endpoint was overall response rate.
Results: In the 48 enrolled patients response rate according was 46.8% (95% CI: 32.54%–61.07%), while 13 patients had
stable disease, for an overall disease control rate of 74.4% (95% CI: 57.8–91.2). Progression free survival was 7.9 months (95%
CI: 5.9–9.8 months) and the median overall survival 20.1 months (95% CI: 15.6–25.7 months). Response rate and progression
free survival has been correlated with baseline albumin and haemoglobin levels. There was one treatment-related death.
Grade 3–4 toxicities were asthenia (4.2%), neurotoxicity (2.1%) and diarrhea 6.3%).
Conclusions: The combination of capecitabine, oxaliplatin and bevacizumab is an effective and safe combination for the
treatment of elderly patients with metastatic CRC.
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Colorectal cancer is a leading cause of cancer related
death in developed countries [1]. Considering the fact
that approximately 60% of cases are diagnosed in pa-
tients 65 years or older and also the steadily growing
elderly population in the developed world, it is expected
that the total number of CRC patients over 65 will rise
significantly in the future and CRC will become a major
health issue in geriatrics [2].
There are numerous challenges regarding the treat-
ment of elderly patients with metastatic CRC (mCRC).
Normal aging results in diminished organ function and
reserves; liver and kidney function declines thus altering
drug metabolism, the risk of coronary artery disease and
arterial thromboembolic events is increased, bone mar-
row reserves are limited and polypharmacy and comor-
bidities must be taken into account when treatment is
planned [3,4]. A number of tools has been developed
that assess functional status and predict chemotherapy
toxicity and risk of death in elderly patients [5,6]. One of
the most widely used tools is the Comprehensive Geriat-
ric Assessment (CGA) which includes functional, med-
ical, psychosocial and nutritional questionnaires [7].
The combination of oxaliplatin and fluorouracil (FOL-
FOX) has been consistently shown to be effective and well
tolerated among fit elderly patients with mCRC in prospect-
ive randomized trials and pooled analyses [8-10]. Moreover,
capecitabine combined with oxaliplatin (XELOX) has been
shown to be non-inferior to FOLFOX, albeit with slightly in-
creased toxicity [10,11]. The addition of the monoclonal
antibody bevacizumab, which targets the Vascular Endothe-
lial Growth Factor-A (VEGF-A) to chemotherapy, including
XELOX [12], is considered standard practice when treating
younger mCRC patients [13]. However, when given to eld-
erly patients there is a concern regarding an increased risk
for arterial thromboembolic events [14]. The combination
of bevacizumab and capecitabine has been shown to be ef-
fective in this setting, resulting in an increased progression
free survival (PFS) in an elderly – specific phase III trial that
was recently published [15]. The combination of bevacizu-
mab with two active chemotherapeutics has not been pro-
spectively assessed in an exclusively elderly population.
The aim of the current study is to examine the efficacy
and safety of the combination of capecitabine, oxaliplatin
and bevacizumab (XELOX/BEV) among elderly patients
with mCRC and to identify predictive and prognostic
factors derived from multidimensional geriatric evalua-
tions that influence response to treatment, progression
free survival (PFS), overall survival (OS) and toxicity.
Methods
Patients
Eligible patients had histologically confirmed unresect-
able locally advanced or metastatic colorectal cancer,were ≥ 70 years old with an Eastern Cooperative Oncol-
ogy Group Performance Status (ECOG PS) of 0 to 2 and
had not received any prior chemotherapy or biologic
agent for metastatic colorectal cancer; adjuvant chemo-
therapy with a fluoropyrimidine was allowed if 6 months
or more had elapsed since its completion. Other eligibil-
ity criteria included measurable disease by Response
Evaluation Criteria in Solid Tumors (RECIST) 1.0; [16]
adequate bone marrow, liver and kidney function de-
fined as Glomerular Filtration Rate (GFR) as calculated
using the Cockcroft-Gault formula ≥30 ml/min; absence
of brain metastases; a life expectancy of at least three
months at enrollment; frail patients as determined by
the Comprehensive Geriatric Assessment (CGA) were
excluded [17]. Other exclusion criteria were the daily
use of aspirin (>325 mg per day), other non-steroidal
anti-inflammatory drugs or anticoagulants at a thera-
peutic dose; and significant cardiovascular disease such
as uncontrolled hypertension, coronary heart disease or
previous stroke. The study has been approved by the
ethics and scientific committees of the participating cen-
ters and all patients gave their written informed consent
in order to enter the study (Scientific Committees and
Committees for Bioethics and Medical Ethics, University
Hospital of Herakleion; University General Hospital of
Alexandroupolis; IASO General Hospital of Athens; Air
Forces Military Hospital of Athens; Laikon General
Hospital; State General Hospital of Larissa; Theagenion
Anticancer Hospital of Thessaloniki).
Treatment
We used a modified XELOX regimen, administered cap-
ecitabine in one week on one week of schedule, since
this is associated with less gastrointestinal adverse events
and hand and foot syndrome [18]. Capecitabine was
given orally at a dose of 750 mg/m2 twice a day during
days 1–7, a regimen that was found to be effective at
a phase II study previously conducted by our group,
albeit with a lower dose due to increased toxicity con-
cerns when combined with both oxaliplatin and beva-
cizumab [18]. The dose was lowered to 625 mg/m2
twice a day if the Glomerular Filtration Rate (GFR), as calcu-
lated using the Cockcroft-Gault formula, was ≤60 ml/min.
Oxaliplatin was given intravenously at a dose of 85 mg/m2
over 240 minutes on day 1. Bevacizumab was given
intravenously at a dose of 5 mg/kg over 60–90 minutes
according to investigator discretion, on day 1. Treat-
ment was administered every two weeks for a total of
12 cycles of chemotherapy except for cases of disease
progression, unacceptable toxicity or consent with-
drawal. Treatment was postponed for 1 week if on
day 1 of each cycle neutrophils were <1500/μL, plate-
lets < 100000/μL and if there were other > grade 2 tox-
icities. If a patient had not recovered after delaying
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study.
The prophylactic use of Granulocyte Colony Stimulating
Factor (G-CSF) was not allowed except for the secondary
prevention of neutropenic fever. Erythropoiesis stimulating
agents were allowed in cases of grade 2 or worse anemia
and were discontinued when haemoglobin levels exceeded
12gr/dL. Pre-specified dose modifications were allowed for
capecitabine and oxaliplatin for grade 3–4 haemotological
adverse events and grade 2–4 non-haematological adverse
events. The dose of bevacizumab was reduced by 50% in
cases of uncontrollable arterial hypertension despite anti-
hypertensive treatment and it was discontinued in cases of
severe haemorrhagic events.
Patient evaluation
Pre-treatment evaluation included a detailed medical his-
tory and physical examination, a complete blood cell count
(CBC) with differential and platelet count, blood chemistry,
serum levels of carcinoembryonic antigen (CEA) and com-
puted tomography scans (CT) of the chest and abdomen.
Patients were clinically assessed before each cycle, CBC
was performed weekly and blood chemistry every two
weeks before treatment administration.
Responses were evaluated with CT scans of the chest
and abdomen and by measuring CEA levels every three
months. Bone scintigraphy and brain CT were performed
based on clinical indication. The Response Evaluation Cri-
teria in Solid Tumors (RECIST) were used to assess tumor
responses. The duration of response was measured from
the first documentation of response to disease progres-
sion. The progression free survival (PFS) was determined
by the interval between the initiation of treatment and the
date when disease progression was first documented or
the date of death from any cause. Overall survival (OS)
was measured from the date of treatment initiation to
the date of death. The follow up time was measured
from the day of first treatment administration to the
time of the present analysis (for patients still alive) or
death for deceased patients.
Toxicities were graded according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) 3.0. All
patients underwent a Comprehensive Geriatric Assess-
ment (CGA) at study enrollment, after the 6th and after
the 12th cycle. The CGA includes questionnaires of daily
(ADL) and instrumental (IADL) activities, the assessment
of performance status, nutritional, mental (Mini Mental
State Examination) and emotional status (Geriatric De-
pression Scale), as well as the evaluation for the presence
of geriatric syndromes, the Charlson’s comorbidities index
and the evaluation of concomitant medications. Patients
were classified as fit if they were independent during ADL
and IADL and there were no geriatric syndromes or co-
morbidities. Patients were classified as vulnerable if theywere dependent on some IADL but not ADL, there were
minor comorbidities but no geriatric syndromes.
Statistical analysis
This multicenter single-arm prospective phase II study
evaluated the efficacy and safety of the XELOX/BEV
combination as front line treatment for elderly patients
with metastatic colorectal cancer. The sample size calcu-
lation was conducted according to an optimal Simon
two-step design testing: The null hypothesis was that the
ORR is ≤ 30% versus the alternative hypothesis that the
ORR is ≥ 40% (α = 0.05, power 80%). An interim analysis
took place on the first 15 patients and as the number of
responders was at least 6, then 31 additional patients
were planned to be enrolled for a total of 46 patients.
The analysis of the primary endpoint was performed
for the intent-to-treat population, defined as all patients
who received at least one treatment cycle in the study.
Patients who withdrew without a response assessment
were classed as non-responders in the analysis. Chi-
square test was used for the association of response with
other dichotomous variables (patients’ age, sex, tumor
stage, etc.). Binary logistic regression was carried out in
order to evaluate which of the significant factors at the
chi-square analysis had a significant influence on re-
sponse. Cox’s proportional hazards multivariate analysis
was used to evaluate which of the significant factors at
the univariate analysis had a significant influence on PFS
and OS. Statistical significance was set at p = 0.05.
Results
Patient characteristics
Between 1/3/2008 and 26/3/2012 48 patients from 11
centers were enrolled. The patients’ demographic and
clinical characteristics are summarized on Table 1. The
median age was 76 years (range: 70 – 86) and 50% (n = 24)
of the patients were female. The median number of meta-
static sites was 2. According to the CGA assessment at
baseline, 52% of the patients were classified as fit and 48%
as vulnerable. The results of multiple geriatric assessment
tools such as the Geriatric Depression Scale, Mini Mental
State Examination, Instrumental Activities of Daily Life
and Charlson Comorbidity Index are shown on Table 1.
Compliance with the treatment
A total of 409 chemotherapy cycles were administered
(median 10, range: 1–16). A total of 41 cycles (10%)
were delayed with a median delay of 9 days (range, 5–66
days). The reason for treatment delay was haematologic
(n = 9 cycles), non-haematologic (n = 5 cycles) toxicity or
both (n = 1 cycle), while in 26 cycles the delay was re-
lated with late admission or response evaluation. Dose
reduction was required in 18 cycles (4.4%) because of
haematological (n = 2 cycles) and non-haematological
Table 1 Patient demographic and clinical characteristics
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sons (n = 4 cycles). Three patients discontinued treat-
ment because of treatment-related toxicity and two
patients withdrew their consent. The mean dose inten-
sity was 4700 mg/m2/week for capecitabine corre-
sponding to the 89.5% of the preplanned protocol
dose, 40 mg/m2/week for oxaliplatin corresponding to
the 94.5% of the preplanned protocol dose and 2.3 mg/
kg/week for bevacizumab corresponding to the 92% of
preplanned dose. G-CSF was not used since none of
the patients developed febrile neutropenia, while ere-
thropoetin was administered in two patients (4%) for
the treatment of grade II anemia. Twenty-three
(47.9%) patients completed the treatment as per proto-
col, 1 patient was lost to follow-up, 2 patients under-
went definitive liver metastasectomy, and 1 patient
discontinued treatment because of an episode of acute
cholecystitis.
Treatment efficacy
Forty-seven patients were evaluable for response to treat-
ment. The study met its primary end point since in an in-
tension to treat analysis, there were four (8.5%) complete
[19] and 18 (38.3%) partial responses (PR), for an overall
response rate of 46.8% (95% CI: 32.5%–61.1%). Thirteen
(27.7%) additional patients had stable disease (SD), for a
disease control rate (CR + PR + SD) of 74.4%. The median
response duration was 7.1 months (range, 1.2–21.0).
After a median follow-up of 15.6 months (range: 0.1–
45.4 months), the median progression free survival was
7.9 months (95% CI: 5.9–9.8 months) and the median
overall survival 20.1 months (95% CI: 15.6–25.7 months).
The probability of 1- and 2-year survival rate were 76.7%
and 42.1%, respectively.
Figure 2 Progression free survival according to baseline
haemoglobin levels.
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found to be affected by baseline albumin levels. Of the
22 patients that had a baseline albumin measurement,
all responses were observed in patients with an albumin
levels >3.5 gr/dL (ORR 50%) compared to patients with
an albumin level <3.5 gr/dL (ORR%; p = 0.030). Response
to treatment was not affected by status according to
comprehensive geriatric assessment (p = 0.634), IADL
score (p = 0.920), MMSE score (p = 0.285), GDS score
(p = 0.151), haemoglobin levels (p = 0.086) or body
mass index (BMI, p = 0.457). PFS was affected by base-
line albumin (10.2 months for albumin ≥3.5 gr/dL ver-
sus 1.1 months for albumin <3.5 gr/dL, p = 0.038) and
baseline haemoglobin [20] levels (8.6 months for Hb ≥
10.5 gr/dL versus 1.1 months for Hb < 10.5 gr/dL, p = 0.007)
(Figures 1 and 2). CGA (p = 0.272), IADL (p = 0.805), MMSE
(p = 0.413), GDS (p = 0.088) and BMI (p = 0.551) did not
affect PFS. Finally, OS was only affected by Hb levels
(17.4 months for Hb ≥ 10.5 gr/dL versus 1.1 months for
Hb < 10.5 gr/dl, p = 0.001) (Figure 3). OS according to
CGA status was 20.7 months for fit patients versus
17.4 months for vulnerable patients, a difference that
could not reach statistical significance. These results were
independent of patients’ age (71–80 vs. 81 or higher), PS,
number of organs involved and Kohne prognostic index.
Toxicity
Treatment related adverse events are summarized on
Table 2. There was one toxic death due to acute respira-
tory distress syndrome attributed to oxaliplatin. The
most common adverse event was grade 1–2 anemia
(79.1%), grade 1–3 asthenia (54.2%; 4.2% grade 3), grade
1–3 neurotoxicity (37.5%) with one patient developing
grade 3 neurotoxicity and grade 1–3 diarrhea (29.2%)
with grade 3 occurring in three patients. There was only
one patient who developed grade 4 arterial hypertensionFigure 1 Progression free survival according to baseline
albumin levels.leading to bevacizumab dose reduction. There were no
thromboembolic episodes. There were only 3 episodes of
grade 3 neutropenia (6.3%) but there was no case of
neutropenic fever. The incidence of adverse events was
not influenced by the patient status (fit vs vulnerable).
Discussion
The treatment of elderly patients with mCRC is still
considered to be a debatable issue. Despite the fact that
the majority of patients are diagnosed in advanced age,
elderly patients under-represented in randomized clin-
ical trials. In addition, the vast majority of elderly pa-
tients included in randomized trials are usually selected
and only fit elderly patients are finally enrolled. Due to
this fact, no definitive conclusion can be drawn regard-
ing the treatment of this population group with mCRC.
The current study describes the results of a chemo-
therapy doublet plus bevacizumab in elderly patients se-
lected upon CGA. Our results show that the triple
combination of XELOX/BEV is effective and well toler-
ated among fit and vulnerable elderly patients withFigure 3 Overall survival according to baseline haemoglobin
levels.
Table 2 Treatment related adverse events
All grades Grades III-IV
N % N %
Leukopenia 12 25.1 - -
Neutropenia 11 23.0 3 6.3
Anemia 38 79.1 - -
Thrombocytopenia 18 37.5 - -
Nausea 11 23.0 2 4.2
Vomiting 9 18.8 2 4.2
Diarrhea 13 27.2 3 6.3
Mucositis 3 6.3 - -
Dysgefsia 1 2.1
Constipation 9 18.8 1 2.1
Abdominal pain 4 8.3
Non cardiac chest pain 1 2.1
Neurotoxicity 18 37.5 1 2.1
Seizures 1 2.1
Headache 3 6.3
Allergic reaction 1 2.1 1 -
Asthenia 264 54.2 2 4.2
Anorexia 5 10.4
Cutaneous toxicity 1 2.1 - -
Fever 2 4.2 - -
Hemorrhage 1 2.1 - -
Hypertension 3 6.3 1 2.1
.1
Hand foot syndrome 1 2.1
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results in younger populations reported in the literature.
Our study has several strengths. First of all, to our
knowledge this is the first study to prospectively assess a
three drugs combination specifically in an elderly-only
population. Designing geriatric-specific chemotherapy
trials has been shown to allow for the prediction of
treatment related toxicities [19]. This is further sup-
ported by our study where the rates of reported adverse
events were very low. Also, compliance was excellent
with very low rates of dose reduction or cycle postpone-
ment. Other strengths of our study include the system-
atic use of comprehensive geriatric assessments and the
homogenous study population, which allowed for careful
dose tailoring which led to high response rates with
minimal toxicity.
On the other hand, our study suffers from several
weaknesses. It is a phase II study with a small number of
patients. As a result, we were unable to identify predict-
ive and prognostic factors derived from the Comprehen-
sive Geriatric Assessments. Also, our study populationwas limited only to fit and vulnerable elderly patients, so
our results may not be representative in frail patients
with mCRC.
Previous studies have established the efficacy and
safety of combination chemotherapy in elderly patients
[8-11]. The addition of bevacizumab to chemotherapy in
geriatric populations has also been shown to be effective
in observational cohort studies, subgroup analyses and
pooled analyses of cohorts of other randomized trials
[20-23]. Recently, the results of the first randomized
Phase III study of capecitabine plus bevacizumab exclu-
sively in elderly patients were published (AVEX trial:
bevacizumab plus capecitabine versus capecitabine in
elderly patients with previously untreated metastatic
colorectal cancer) [15]. Taking into account the inherent
hazards of cross-study comparisons, OS was similar be-
tween the AVEX trial and our study. However, response
rates were higher with the triple drug combination and
adverse events were lower. In addition, the patient popu-
lation in the AVEX study was quite different since it was
based on clinical judgment that the patient was not suit-
able for oxaliplatin or irinotecan-based doublets. It
seems that the next logical step would be to directly
compare these two regimens; until such data are available,
modified XELOX/BEV might be an alternative option for
patients requiring a relatively rapid and objective clinical
response, such as in patients with potentially resectable
disease or in those with rapidly progressive disease and/or
with a need for symptoms relief.Conclusion
In conclusion, our data suggest that the combination of
XELOX/BEV combination is an attractive and alternative
regimen for fit and vulnerable elderly patients with
mCRC, with high response rates and low toxicity. Also,
the use of CGA at baseline may be considered as a tool
capable to differentiate elderly patients who are fit
enough to tolerate a more intensive treatment. Further
evaluation in randomized trials is needed in order to
confirm these observations.Competing interests
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